Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

Alphamab Oncology’s JSKN033 Gets Green Light for Phase I/II Study from China’s CDE

Fineline Cube Dec 25, 2024

China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...

Company Drug

CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment

Fineline Cube Dec 24, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...

Company Drug

Keymed Biosciences’ Kangyueda Approved for CRSwNP Treatment in China

Fineline Cube Dec 24, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced that it has received another indication approval...

Company Drug

Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases

Fineline Cube Dec 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial

Fineline Cube Dec 24, 2024

China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...

Company Drug

AstraZeneca’s Tagrisso Secures EU Approval for EGFR-Mutated Locally Advanced NSCLC

Fineline Cube Dec 24, 2024

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that the European Commission (EU) has...

Company Deals

Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’

Fineline Cube Dec 24, 2024

US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger...

Company Deals

Sanofi and SK bioscience Broaden Partnership to Develop Next-Gen Pneumococcal Vaccines

Fineline Cube Dec 24, 2024

French pharmaceutical major Sanofi (NASDAQ: SNY) and South Korea-based SK bioscience (KRX: 302440) have announced...

Company Deals

Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage

Fineline Cube Dec 24, 2024

China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...

Company Drug

ETERN Therapeutics’ YAP/TEAD Inhibitor ETS-006 Wins FDA Clinical Approval for Advanced Solid Tumors

Fineline Cube Dec 24, 2024

China-based biopharmaceutical company ETERN Therapeutics has announced that it has received clinical approval from the...

Company Drug

Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC

Fineline Cube Dec 24, 2024

Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing...

Company Drug

Roche’s Lunsumio Receives NMPA Approval for R/R Follicular Lymphoma Treatment

Fineline Cube Dec 24, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received marketing approval from...

Company

BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”

Fineline Cube Dec 24, 2024

China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a...

Company Deals

RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904

Fineline Cube Dec 24, 2024

US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the...

Company Deals

Porton Pharma and Dragon Sail Join Forces to Enhance ADC Drug Development

Fineline Cube Dec 24, 2024

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has entered into a strategic...

Company Drug

GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial

Fineline Cube Dec 23, 2024

UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44...

Company Drug

Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment

Fineline Cube Dec 23, 2024

US-based Pfizer (NYSE: PFE) has announced receiving an indication extension approval from the US Food...

Company Drug

Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity

Fineline Cube Dec 23, 2024

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food...

Company Drug

Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis

Fineline Cube Dec 23, 2024

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration...

Company

Boehringer Ingelheim-SEC Joint Incubator Launches in Shenzhen’s Luohu District

Fineline Cube Dec 23, 2024

On December 23, the Boehringer Ingelheim-SEC Joint innovative incubator was inaugurated in Luohu District, Shenzhen....

Posts pagination

1 … 247 248 249 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.